Navigation Links
Manchester patients take part in pioneering heart attack blood test trial
Date:2/27/2013

Dr Richard Body, Consultant in Emergency Medicine at MRI and Honorary Lecturer in Cardiovascular Medicine at The University of Manchester, is leading the research team and Manchester is the only location in the UK where the trial is taking place. He was invited by Roche, the blood test manufacturer, to take part in the trial as he specialises in research into better and faster ways to diagnose heart attacks. The other trial sites are in Australia, Belgium, France, Germany, Italy, Spain, Sweden, Switzerland and the USA, with 1400 patients taking part in total.

Working with Dr. Body, research nurses, Andy Brown and Richard Clark answered any questions patients had about the trial and took a series of blood samples. The team is also following up all the patients in the trial over the next 12 months to check how they are recovering.

"This study could potentially make a huge difference to the way staff in emergency departments diagnose heart attacks and the subsequent treatment options for patients," said Dr Body. "If we can rule out a heart attack in as little as an hour, this is reassuring for patients, reduces the likelihood of them being admitted to hospital, prevents any unnecessary treatment and means we can look for other causes of their chest pain.

"Equally, if we know we are definitely dealing with a heart attack we can transfer patients to the right specialist cardiac services without wasting any time and so boost their chances of making a full recovery."

The next steps in the trial involve all the blood samples from the 14 participating sites being submitted to a central laboratory for analysis over the coming 12 months. This will include assessing factors that can affect troponin levels, such as gender, age, high blood pressure or cholesterol and health conditions such as heart disease or diabetes. Dr Body and his international colleagues will then spend time looking at the results to see if the blood troponin test is as fast and accurate as anticipated. They hope to have definitive results by mid-2014.

"The researchers involved in the trial are very influential in the emergency medicine field. If the trial is a success, Manchester will have contributed to changing international standards of diagnosis and care for all heart attack patients," added Dr Body.


'/>"/>
Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related biology news :

1. Researchers in Manchester find genetic key to preventing spine tumors
2. BESAFE Conference in Manchester: Working towards a brighter future for biodiversity
3. Reproductive health providers should discuss environmental exposure risks with patients
4. Low-calorie diet may be harmful for bowel disease patients
5. Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
6. Interventional radiologists see significant symptom relief in MS patients
7. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
8. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
9. Obese patients face higher radiation exposure from CT scans -- but new technology can help
10. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
11. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):
(Date:5/15/2017)... ... May 15, 2017 , ... Tunnell Consulting announced that Julia ... Key Role of Specifications in Process Validation,” at the Process Validation Summit 2017, ... bring together leaders from the pharmaceutical and biotech industries to explore processes, strategies and ...
(Date:5/15/2017)... Glendale, Calif. (PRWEB) , ... May 15, 2017 ... ... with today’s launch of ELEVATE Advanced Lift Contouring Cream, a gravity-shattering cream with ... , “We’re thrilled to bring the Advanced Lift Contouring Cream to ...
(Date:5/15/2017)...  IBM (NYSE: IBM ) scientists have ... DNA molecules with the potential to efficiently reveal ... technology complements the IBM Research,s "lab-on-a-chip" nanoDLD ... and which may also contain biomarkers for disease ... of diamond shaped micropillars 1 to pre-stretch ...
(Date:5/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... investigational treatment for the prevention of episodic and ... Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) demonstrating ... migraine headache days compared to placebo at both ... from these three studies bring us one step ...
Breaking Biology Technology: